Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

Inclusion Criteria: 1. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol; 2. Age 18 to 70 years old; 3. Advanced Colorectal Cancer that progresses after first-line chemotherapy； 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 5. Expected survival time of ≥ 12 weeks; 6. Good function of vital organs; 7. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling; 8. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling. Exclusion Criteria: 1. Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry; 2. Known mental illness, alcoholism, drug use or substance abuse; 3. Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion; 4. Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study; 5. The investigators determine that other conditions that make the patient not suitable for enrollment